AMENDMENTS TO THE CLAIMS

1-21. (Cancelled)

22. (Currently Amended) A pharmaceutical composition comprising as active principle at least one among the 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I), or their dimers of general formula (II) and (III), or mixtures thereof

wherein:

R₁ is and R'₁, equal or different between each other, are selected from the group consisting of H, C₁salkyl, C₂-salkenyl, C₂-salkynyl, cycloalkyl, aryl, heterocycle, arylC₁-salkyl; heterocycleC₁-salkyl,
RR'N-C₁-salkyl, RR'N-aryl, FmocNR' aryl, BocNR' aryl, CBzNR' aryl, RO-aryl, R(O)C-aryl,
RO(O)C-aryl, RR'N(O)C-aryl; FmocNR' C₁-salkyl, BocNR' C₁-salkyl, CbzNR' C₁-salkyl,
FmocNR' C₁-saryl, BocNR' C₁-saryl and CbzNR' C₁-s aryl,

R₂ and R'₂, equal or different between each other, are <u>is</u> selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, aryl, arylC₁₋₈alkyl, heterocycleC₁₋₈alkyl, aminoC₁₋₈alkyl, aminoC₁₋₈alkyl, aminoC₁₋₈alkyl, carboxyC₁₋₈alkyl, methyloxycarbonylC₁₋₈alkyl, carboxyaryl, carboalkyloxyaryl, alkylcarbamoylaryl and -(side chains of amino acids), or R₁ and R₂, taken together, and R₁' and R₂', taken together, are C₁₋₄alkyl, C₂₋₄alkenyl, cycloalkyl or benzofused cycloalkyl, to form a bridge of 3, 4, 5, 6 terms,

R₃ and R₃' are is selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, aryl, arylC₁₋₈alkyl, heterocycleC₁₋₈alkyl, RR'NC₁₋₈alkyl, RR'Naryl, RO-C₁₋₈alkyl, RO(O)C-C₁₋₈alkyl, RC(O)O-C₁₋₈alkyl, RC(O)N(R)C₁₋₈alkyl, RO-aryl, RO(O)C-aryl, RC(O)O-aryl, RC(O)N(R)aryl, -CH(amino acid side-chain)CO₂R, -CH(amino acid side-chain)CO₂N, -CH(CO₂R)- amino acid side-chain, CH(CONRR')- amino acid side-chain, Fmoc, Boc and Cbz,

R₄, and R'₄-R₅, and R'₅, equal or different amongst each other, are selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkinyl, cycloalkyl, aryl, heterocycle, arylC₁₋₈alkyl and heterocycleC₁₋₈alkyl,

R₆ is selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, aryl, arylC₁₋₈alkyl, heterocycle, heterocycleC₁₋₈alkyl; -C(O)R, -C(O)OR, -C(O)NRR', CH₂OR, CH₂NRR', -C(O)NH-CH(amino acid side-chain)C(O)OR, CH₂NR-Fmoc, CH₂NR-Boc and CH₂NR-CBz, R and R', equal or different between each other, are selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, aryl, heterocycle, arylC₁₋₈alkyl; heterocycleC₁₋₈alkyl; protecting group, -C(O)CH-(amino acid side-chain)-NHT, -NH-CH(amino acid side-chain)COOT and -CH(amino acid side-chain)COOT,

where T is selected from between H and C₁₋₈alkyl;

X is and X', equal or different between each other, are selected from between O and S, when a is a double bond, or

X and X' are both H, when a is a single bond,

Y and Z, equal or different from each other, are selected from the group consisting of O, S, SO, SO₂ and N-R, wherein R is as above defined;

Q is selected from the group consisting of C=O, CH₂, CO-NH-CH (amino acid side-chain)-CO, CONR(CH₂)_nCO, CONR-C₂₋₈alkenyl-CO C(O)O(CH₂)_nCO, CH₂OC(O)(CH₂)_nCO, and CH₂NRC(O)(CH₂)_nCO, wherein n is comprised between 2 and 6, and R is as above defined, Q' is selected from the group consisting of C(O)OCH₂, C(O)NRCH₂, CH₂OC(O), CH₂NRC(O), CONR(CH₂)_nNRCO, CONR-C₂₋₈alkenyl-NRCO, C(O)O(CH₂)_nNRCO, CONR(CH₂)_nOC(O), CH₂OC(O)(CH₂)_nOC(O)CH₂, CH₂NRC(O)(CH₂)_nNRC(O)CH₂, CH₂OC(O)(CH₂)_nNRC(O)CH₂, CH₂OC(O)(CH₂)_nNRC(O)CH₂, CH₂NRC(O)(CH₂)_nNRCH₂, CH₂O(CH₂)_nOCH₂, CH₂O(CH₂)_nNRCH₂, and CH₂NR(CH₂)_nOCH₂, wherein n is comprised between 2 and 6, and R is as above defined, and where the groups alkyl, alkenyl, alkynyl, cycloalkyl, aryl and the heterocyclic groups above reported, are possibly substituted;

wherein said pharmaceutical composition is for use in the treatment of diseases in which neurotrophine functions are involved in defect.

- 23. (Currently Amended) The pharmaceutical composition according to claim 22, wherein in 3-aza-bicyclo[3.2.1]octane derivatives of formula (I) and in their dimers of formula (II) Z is O.
- 24. (Previously Presented) The pharmaceutical composition according to claim 22, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heterocyclic groups may be substituted with one or more moieties chosen from the group consisting of halogen, cyano, nitro, amino, hydroxy, carboxylic acid, carbonyl and C_{1-6} alkyl.
- 25. (Currently Amended) The pharmaceutical composition according to claim 22, wherein the 3-aza-bicyclo[3.2.1]octane derivatives of formula (I) and their dimers of formula (II) and (III) are selected from the compounds having the following formulas:

	R_3 R_1 R_6									
			X	(I)						
Compound	X	R_1	R ₂	R ₃	R ₆					
1	О	Н	H	PhCH ₂	(R) -CO ₂ Me					
2	О	Н	Н	PhCH ₂	(S) -CO ₂ Me					
3	O	Н	Н	PhCH ₂	(R)-CON					
4	O	Н	Н	PhCH ₂	(R)-CON					
5	0	Н	(S) -Me	PhCH ₂	(R) -CO ₂ Me					
6	О	Н	(S) -Me	PhCH ₂	(S) -CO ₂ Me					

7	О	Н	(R) -Me	PhCH ₂	(R) -CO ₂ Me
8	0	H	(R) -Me	PhCH ₂	(S) -CO ₂ Me
9	О	Н	(R) -CH ₂ Ph	PhCH ₂	(S) -CO ₂ Me
10	О	Н	(R) -CH ₂ Ph	PhCH ₂	(R) -CO ₂ Me
11	О	H	(S) -CH ₂ Ph	PhCH ₂	(S) -CO ₂ Me
12	О	Н	(S) -CH ₂ Ph	PhCH ₂	(R) -CO ₂ Me
13	О	Н	(S)-CH ₂ OBn	PhCH ₂	(R) -CO ₂ Me
14	О	Н	(S)-CH ₂ OBn	PhCH ₂	(S) -CO ₂ Me
15	О	Н	(R)-CH ₂ OBn	PhCH ₂	(R) -CO ₂ Me
16	О	Н	(R)-CH ₂ OBn	PhCH ₂	(S) -CO ₂ Me
17	О	Н	(S)-CH ₂ OH	PhCH ₂	(R) -CO ₂ Me
18	О	Н	(S)-CH ₂ OH	PhCH ₂	(S) -CO ₂ Me
19	О	Н	(R)-CH ₂ OH	PhCH ₂	(R) -CO ₂ Me
20	О	Н	(R)-CH ₂ OH	PhCH ₂	(S) -CO ₂ Me
21	О	Н	=CH ₂	PhCH ₂	(R) -CO ₂ Me
22	О	Н	=CH ₂	PhCH ₂	(S) -CO ₂ Me
23	О	H	(R)-CH ₂ OH	PhCH ₂	(S) -CO ₂ Me
24	S	H	H	PhCH ₂	(R) -CO ₂ Me
25	S	H	Ħ	PhCH ₂	(R)-CONH(CH ₂) ₂ NH ₂
26	S	H	H	PhCH ₂	(R)-CONH(CH ₂) ₂ OH
27	О	Ph	H	PhCH ₂	(R) -CO ₂ Me
28	θ	Ph	H	PhCH ₂	(S) -CO ₂ Me
29	θ	Ph	H	CH(Ph) ₂	(R)-CO ₂ Me
30	θ	Ph	H	CH(Ph) ₂	(S) CO ₂ Me
31	θ	NO ₂ -Ph	H	Ph	-(S)-CO ₂ Me
32	H	Ħ	H	H	(<i>R</i>)—CO₂H
33	H	H	H	H	(S)—CO ₂ H
34	H	H	H	H	(R)-CO ₂ Me

35	H	Ħ	Ħ	H	(S) -CO ₂ Me
36	H	Ħ	H	PhCH ₂	(R) -CO ₂ H
37	H	Ħ	H	PhCH ₂	(S)CO ₂ H
38	H	H	Ħ	Fmoc	(R)—CO ₂ H
39	H	H	H	Fmoc	(S)—CO ₂ H
40	Ħ	H	H	PhCH ₂	(R) -CO ₂ Me
41	H	Ħ	H	PhCH ₂	(S) -CO ₂ Me
42	H	Ħ	Ħ	Boc	(R)—CO ₂ Me
43	Ħ	Ħ	H	Boc	(S)—CO ₂ Me
44	Ħ	Ħ	H	Fmoc	(R)—CO₂Me
45	Ħ	Ħ	H	Fmoe	(S) CO ₂ Me
46	Ħ	Ħ	Ħ	H	(R) -CONHMe
47	Ħ	Ħ	Ħ	H	(S)—CONHMe
48	Ħ	Ħ	H	Ae	(R) -CONHMe
49	H	Ħ	H	Ae	(S) -CONHMe
50	H	Ħ	H	PhCH ₂	(R) -CONHMe
51	H	H	H	PhCH₂	(S) -CONHMe
52	H	Ħ	Ħ	Fmoc	(R) -CONHMe
53	Ħ	H	H	Fmoc	(S) -CONHMe
54	H	H	H	PhCH ₂	(R)-CON
55	H	H	H	PhCH ₂	(R) -CONH
56	H	H	H	PhCH ₂	
					(R) CON
57	H	H	Ħ	PhCH ₂	(R)-CONH(CH ₂) ₂ OH
58	H	H	H	H	(R) -CH ₂ OH

59	Ħ	Ħ	Ħ	H	(S) -CH2OH
60	H	Ħ	Ħ	Fmoc	(S) -CH ₂ OH
61	Ħ	Ħ	Ħ	Fmoc	(R)—CH₂OH
62	H	Ħ	Ħ	Boe	(R)—CH ₂ OH
63	H	Ħ	H	Boc	(S) -CH ₂ OH
64	H	H	H	PhCH ₂	(R) -CH ₂ OH
65	H	H	H	PhCH ₂	(S) -CH ₂ OH
66	H	H	(S) -CH ₂ OBn	PhCH ₂	(R) -CO ₂ Me
67	H	Ħ	(S) -CH ₂ OBn	PhCH ₂	(S) -CO ₂ Me
68	H	H	(R)—CH ₂ OBn	PhCH ₂	(R) -CO ₂ Me
69	H	H	(R)—CH ₂ OBn	PhCH ₂	(S) -CO ₂ Me
70	H	H	(S)—CH ₂ OBn	PhCH ₂	(R) -CH ₂ OH
71	Ħ	H	(S) -CH ₂ OBn	PhCH₂	(S) -CH ₂ OH
72	Ħ	H	(R) -CH ₂ OBn	PhCH ₂	(R) -CH ₂ OH
73	H	H	(R)—CH ₂ OBn	PhCH ₂	(S) -CH ₂ OH
75	Ħ	H	(S) -COOH	Fmoc	(R) -CO ₂ Me
76	H	H	(S) COOH	Fmoc	(S) -CO ₂ Me
77	Ħ	H	(R) -COOH	Fmoc	(R) CO ₂ Me
78	Ħ	Ħ	(R) -COOH	Fmoc	(S) -CO ₂ Me
79	H	H	(S) -CH ₂ OBn	Fmoc	(R) CO ₂ Me
80	H	Ħ	(S) -CH ₂ OBn	Fmoc	(S) -CO ₂ Me
81	Ħ	H	(R) -CH ₂ OBn	Fmoc	(R) -CO ₂ Me
82	H	H	(R)—CH ₂ OBn	Fmoc	(S)—CO ₂ Me
83	H	H	(S)—CH ₂ OBn	H	(R) -CO ₂ Me
84	Ħ	H	(S)—CH ₂ OBn	H	(S) -CO ₂ Me
85	H	H	(R)—CH₂OBn	H	(R) −CO ₂ Me
86	H	H	(R)—CH₂OBn	H	(S)—CO ₂ Me
87	H	H	(S)—CH ₂ OH	H	(R) -CO ₂ Me
88	H	H	(S)—CH ₂ OH	Ħ	(S)—CO ₂ Me

89	H	H	(R) -CH ₂ OH	H	(R) -CO ₂ Me
90	H	H	(R) -CH ₂ OH	H	(S)—CO ₂ Me
91	H	H	(S) -CH ₂ OH	Fmoc	(R) -CO ₂ Me
92	H	H	(S) -CH ₂ OH	Fmoe	(S)—CO ₂ Me
93	H	H	(R) CH ₂ OH	Fmoe	(R)—CO ₂ Me
94	H	H	(R) -CH₂OH	Fmoe	(S) -CO ₂ Me
95	H	H	(S) -CH2OH	Fmoc	(R) -CO ₂ Me
96	H	H	(S) -CH ₂ OH	Fmoc	(S) -CO ₂ Me
97	H	H	(Я)—СН2ОН	Fmoc	(R)—CO ₂ Me
98	H	H	(R)—CH ₂ OH	Fmoc	(S) -CO ₂ Me
99	H	Ħ	(S)—CH ₂ OH	PhCH ₂	(S) -CO ₂ Me
100	H	H	(R)—CH ₂ OH	PhCH ₂	(R) -CO ₂ Me
101	H	Ħ	(R)—CH ₂ OH	PhCH ₂	(R) -CO ₂ Me
102	H	Ħ	(R) CH ₂ OH	PhCH ₂	(S) -CO ₂ Me
103	H	H	(S)—CH2OH	Fmoc	(R)—CH₂OH
104	H	H	(S)—CH2OH	Fmoc	(S)—CH ₂ OH
105	Ħ	H	(R) -CH₂OH	Fmoc	(R)—CH₂OH
106	Ħ	H	(R) -CH₂OH	Fmoc	(S)—CH ₂ OH
107	Ħ	H	(S) -CH₂OH	PhCH ₂	(R) -CH₂OH
108	H	H	(S) -CH₂OH	PhCH ₂	(S) CH ₂ OH
109	H	H	(R)—CH₂OH	PhCH ₂	(R) -CH ₂ OH
110	Ħ	H	(R) -CH₂OH	PhCH ₂	(S) -CH ₂ OH
111	H	H	=CH ₂	PhCH ₂	(<i>R</i>)—CO₂Me
112	H	H	=CH ₂	$PhCH_2$	(S) -CO ₂ Me
113	H	H	=CH ₂	PhCH ₂	(R)-CH₂OH
114	H	H	=CH ₂	PhCH ₂	(S) -CH₂OH
115	H	H	(S)-CH ₂ CH(Me) ₂	Fmoc	(R) -CH ₂ OH
116	H	H	(S)-CH ₂ CH(Me) ₂	PhCH ₂	(S) -CH ₂ OH
117	H	Ħ	(S)-CH ₂ CH(Me) ₂	H	(R)—CH ₂ OH

118	H	Ph	H	H	(R)—CO ₂ Me
119	H	Ph	H	Fmoc	(R) CO ₂ Me
120	H	Ph	Ħ	PhCH ₂	(R) CO ₂ Me
121	Ħ	Ph	Ħ	CH(Ph) ₂	(R) -CO ₂ Me
122	H	Ph	H PhCH2 H CH(Ph)2 H H H H PhCH2 H PhCH2 H PhCH2 H PhCH2 H Ph		(S)—CO ₂ Me
123	Ħ	Ph	Ħ	Fmoc	(S)—CO ₂ Me
124	H	Ph			(S) -CO ₂ Me
125	H	Ph	H	CH(Ph) ₂	(S)—CO ₂ Me
126	H	p-NH ₂ -C ₆ H ₄	H	Ph	-(S)-COOMe
127	H	p-NH ₂ -C ₆ H ₄	H Ph (S)		-(S)-COOH
128	H	p-NH ₂ -C ₆ H ₄	H	Ph	(S)-CONHCH ₂ CO ₂ Me
129	Ħ	p-NH-	Ħ	Ph	-(S)-CO ₂ Me
		(Asp(O ^t Bu)-			
		NH2) C6H4			
130	H	p-NH-	Ħ	Ph	-(S)-CO ₂ H
		(Asp(O ^t Bu)N			
		H ₂)-C ₆ H ₄			
131	H	p-NH-	Ħ	Ph	(S)-CONH-
		(Asp(O ^t Bu)-			Lys(NHBoc)-OMe
		NH ₂) C ₆ H ₄			
132	H	p-NH-	H	Ph	(S)-CONH-Lys-OMe
		(Asp(OH)-		•	
		NH ₂)-C ₆ H ₄			
133	H	p-NO ₂ -C ₆ H ₄	Ħ	Ph	-(S)-COOH
134	H	p-NO ₂ -C ₆ H ₄	Ħ	Ph	-(S)-COOMe
135	H	p-NO ₂ -C ₆ H ₄	Ħ	Ph	-(S)-CONHCH ₂ CO ₂ Me
136	H	Ph	H	H	(R) -CH ₂ OH
137	Ħ	Ph	Ħ	Fmoc	(R) −CH ₂ OH
138	Ħ	Ph	Ħ	PhCH ₂	(R) −CH ₂ OH

139	Ħ	Ph	H	CH(Ph) ₂	(R) -CH ₂ OH
140	H	Ph	Ħ	Ħ	(S)—CH ₂ OH
141	H	Ph	Ħ	Fmoc	(S)—CH ₂ OH
142	Ħ	Ph	Ħ	PhCH ₂	(S)—CH ₂ OH
143	H	Ph	H	CH(Ph) ₂	(S)—CH ₂ OH
144	H	H	(S) -Me	Fmoc	(<i>R</i>) −CO ₂ H
145	H	H	(S)—Me	Fmoc	(S) —CO₂H
146	H	H	(R) -Me	Fmoc	(R) -CO ₂ H
147	H	H	(R) -Me	Fmoc	(S)—CO₂H
148	Ħ	Ħ	(S) -Me	Fmoc	(R) -CO ₂ Me
149	Ħ	Ħ	(S) -Me	Fmoc	(S)—CO ₂ Me
150	Ħ	Ħ	(R) -Me	Fmoc	(R) -CO ₂ Me
151	Ħ	H	(R) -Me	Fmoc	(S) CO ₂ Me
152	Ħ	H	(S) -Me	PhCH ₂	(R) -CO ₂ Me
153	Ħ	H	(S)—Me	PhCH ₂	(S)—CO ₂ Me
154	H	H	(R) -Me	PhCH ₂	(R) -CO ₂ Me
155	H	H	(R)—Me	PhCH ₂	(S)—CO ₂ Me
156	H	H	(S)—Me	Fmoc	(R)—CH ₂ OH
157	H	H	(S)—Me	Fmoc	(S)—CH ₂ OH
158	Ħ	H	(R)—Me	Fmoc	(R)—CH ₂ OH
159	Ħ	H	(R)—Me	Fmoc	(S)—CH ₂ OH
160	H	H	(S) -Me	PhCH ₂	(R) -CH ₂ OH
161	Ħ	H	(S)—Me	PhCH ₂	(S)—CH ₂ OH
162	H	Ħ	(R) -Me	PhCH ₂	(R) -CH ₂ OH
163	H	H	(<i>R</i>)—Me	PhCH ₂	(S) -CH₂OH
164	H	H	(S) -PhCH ₂	Fmoc	(R) -CO₂H
165	Ħ	H	(S) PhCH ₂	Fmoc	(S)—CO ₂ H
166	Ħ	H	(R) -PhCH ₂	Fmoc	(R) -CO₂H
167	H	H	(R) -PhCH ₂	Fmoc	(S)—CO ₂ H

168	H	H	(S) -PhCH ₂	Fmoc	(R)—CO ₂ Me
169	H	Ħ	(S) PhCH ₂	Fmoc	(S)—CO ₂ Me
170	H	H	(R)—PhCH ₂	Fmoe	(R) −CO ₂ Me
171	Ħ	H	(R)—PhCH ₂	Fmoc	(S) -CO ₂ Me
172	Ħ	H	(S) -PhCH ₂	PhCH ₂	(R) CO ₂ Me
173	Ħ	H	(S) PhCH ₂	PhCH ₂	(S) -CO ₂ Me
174	Ħ	H	(R)—PhCH ₂	PhCH ₂	(R) CO ₂ Me
175	Ħ	Ħ	(R)—PhCH ₂	PhCH ₂	(S) -CO ₂ Me
176	Ħ	H	(R) PhCH ₂	H	(R)—CO ₂ Me
177	H	Ħ	(R)—PhCH ₂	H	(S) -CO ₂ Me
178	Ħ	H	(S) -PhCH ₂	H	(R) -CO ₂ Me
179	Ħ	Ħ	(S) PhCH ₂	H	(S) -CO ₂ Me
180	Ħ	H	(S) -PhCH ₂	Fmoc	(R) -CH ₂ OH
181	H	Ħ	(S) PhCH ₂	Fmoc	(S)—CH ₂ OH
182	Ħ	H	(R)—PhCH ₂	Fmoc	(R) -CH ₂ OH
183	Ħ	H	(R) PhCH ₂	Fmoc	(S) -CH ₂ OH
184	Ħ	H	(S)—PhCH ₂	PhCH ₂	(R) -CH ₂ OH
185	Ħ	H	(S) -PhCH ₂	PhCH ₂	(S) -CH ₂ OH
186	H	Ħ	(R)—PhCH ₂	PhCH ₂	(R) -CH₂OH
187	Ħ	H	(R) -PhCH ₂	PhCH ₂	(S) -CH ₂ OH
188	Ħ	Ħ	(S)-PhCH ₂	PhCH ₂	(R) -COOH
189	θ	p-NO ₂ Ph	H	Ph	CONH(CH ₂) ₆ NH ₂


100	T	77	TT	DI CIT	(B) CO M
190	0	H	Н	PhCH ₂	(R) -CO ₂ Me
191	0	H	Н	PhCH ₂	(S) -CO ₂ Me
192	0	Н	(S) -Me	PhCH ₂	(R) -CO ₂ Me
193	0	Н	(S) -Me	PhCH ₂	(S) -CO ₂ Me
194	О	Н	(R) -Me	PhCH ₂	(R) -CO ₂ Me
195	0	Н	(R) -Me	PhCH ₂	(S) -CO ₂ Me
196	О	H	(S) -PhCH ₂	PhCH ₂	(R) -CO ₂ Me
197	О	Н	(S) -PhCH ₂	PhCH ₂	(S) -CO ₂ Me
198	0	Н	(R) -PhCH ₂	PhCH ₂	(R) -CO ₂ Me
199	0	Н	(R) -PhCH ₂	PhCH ₂	(S) -CO ₂ Me
200	О	H	(S) -CH ₂ CH(Me) ₂	PhCH ₂	(R) -CO ₂ Me
201	0	Н	(S) -CH ₂ CH(Me) ₂	PhCH ₂	(S) -CO ₂ Me
202	0	Н	(R) -CH ₂ CH(Me) ₂	PhCH ₂	(R) -CO ₂ Me
203	О	Н	(R) -CH ₂ CH(Me) ₂	PhCH ₂	(S) -CO ₂ Me
204	О	Н	Н	PhCH ₂	(R) -CONHMe
205	О	Н	Н	PhCH ₂	(S) -CONHMe
206	0	Н	(S) -Me	PhCH ₂	(R) -CONHMe
207	О	Н	(S) -Me	PhCH ₂	(S) -CONHMe
208	0	Н	(R) -Me	PhCH ₂	(R) -CONHMe
209	О	Н	(R) -Me	PhCH ₂	(S) -CONHMe
210	О	Н	(S) -PhCH ₂	PhCH ₂	(R) -CONHMe
211	О	Н	(S) -PhCH ₂	PhCH ₂	(S) -CONHMe
212	О	Н	(R) -PhCH ₂	PhCH ₂	(R) -CONHMe
213	О	Н	(R) -PhCH ₂	PhCH ₂	(S) -CONHMe
214	О	Н	(S) -CH ₂ CH(Me) ₂	PhCH ₂	(R) -CONHMe
215	О	Н	(S) -CH ₂ CH(Me) ₂	PhCH ₂	(S) -CONHMe
216	О	Н	(R) -CH ₂ CH(Me) ₂	PhCH ₂	(R) -CONHMe
217	0	Н	(R) -CH ₂ CH(Me) ₂	PhCH ₂	(S) -CONHMe
218	H	Ħ	H	Fmoc	(R) −CO ₂ H
t			···		

219	H	H	Ħ	Fmoe	(R)—CO ₂ Me
220	Ħ	Ħ	Ħ	Fmoe	(S)—CO ₂ H
221	H	H	H	Fmoe	(S)—CO ₂ Me
222	H	Ħ	(S)-Me	Fmoc	(R)—CO ₂ H
223	H	H	(S)-Me	Fmoc	(R)—CO ₂ Me
224	H	H	(S)-Me	PhCH ₂	(R)—CO ₂ Me
225	Ħ	Ħ	(<i>R</i>)-Me	Fmoe	(R) −CO ₂ H
226	H	H	(<i>R</i>)-Me	Fmoe	(R)—CO ₂ Me
227	H	Ħ	. (R)- Me	PhCH ₂	(R) CO ₂ Me
228	H	H	(S)-Me	Fmoc	(S)—CO ₂ H
229	Ħ	H	(S)-Me	Fmoc	(S) -CO ₂ Me
230	Ħ	H	(S)-Me	PhCH ₂	(S)—CO₂Me
231	H	H	(R)-Me	Fmoc	(S) -CO ₂ H
232	H	Ħ	(R)-Me	Fmoc	(S) -CO ₂ Me
233	H	H	(R)-Me	PhCH ₂	(S) CO ₂ Me
234	H	Ħ	(S)-PhCH ₂	Fmoc	(R) -CO ₂ H
235	Ħ	Ħ	(S)-PhCH ₂	Fmoc	(R) −CO ₂ Me
236	H	Ħ	(S)-PhCH ₂	PhCH ₂	(R) -CO ₂ Me
237	H	H	(R)-PhCH ₂	Fmoc	(R) -CO ₂ H
238	H	Ħ	(R) PhCH ₂	Fmoc	(R) -CO ₂ Me
239	H	Ħ	(R)-PhCH ₂	PhCH ₂	(R)—CO ₂ Me
240	H	H	(S)-PhCH ₂	Fmoc	(S) -CO ₂ H
241	H	Ħ	(S)-PhCH ₂	Fmoc	(S) CO ₂ Me
242	H	Ħ	(S)-PhCH ₂	PhCH ₂	(S) -CO ₂ Me
243	H	H	(R)-PhCH ₂	Fmoc	(S) −CO ₂ H
244	Ħ	Ħ	(R)-PhCH ₂	Fmoc	(S) -CO ₂ Me
245	H	H	(R)-PhCH ₂	PhCH ₂	(S) -CO ₂ Me
246	Ħ	Ħ	(R)−CH ₂ OH	Fmoc	(S) CO ₂ Me
247	H	H	(R)-CH₂OH	PhCH ₂	(S) CO ₂ Me

248	H	Ħ	(R)-CH ₂ OBn	Fmoe	(S)—CO ₂ Me
249	Ħ	H	(R)−CH ₂ OBn	PhCH ₂	(S)—CO ₂ Me
250	Ħ	Ħ	(R)−CH ₂ OH	Fmoc	(<i>R</i>)CO₂Me
251	Ħ	H	(R)-CH ₂ OH	PhCH ₂	(R)—CO ₂ Me
252	H	Ħ	(R)-CH ₂ OBn	Fmoc	(R) CO ₂ Me
253	Ħ	H	(R)−CH ₂ OBn	PhCH ₂	(R) -CO₂Me
254	Ħ	Ħ	(S)- CH ₂ OH	Fmoc	(S) -CO₂Me
255	H	H	(S)−CH ₂ OH	PhCH ₂	(S) -CO ₂ Me
256	H	· H	(S)- CH ₂ OBn	Fmoc	(S) -CO ₂ Me
257	H	H	(S)−CH ₂ OBn	PhCH ₂	(S) -CO ₂ Me
258	H	H	(S)- CH₂OH	Fmoc	(R) -CO ₂ Me
259	Ħ	H	(S)−CH₂OH	PhCH ₂	(R) -CO ₂ Me
260	H	H	(S)− CH ₂ OBn	Fmoc	(R) -CO ₂ Me
261	H	H	(S)−CH ₂ OBn	PhCH ₂	(R) -CO ₂ Me
262	H	Ħ	(S)-CH ₂ CH(Me) ₂	Bn	(R)CO₂Me
263	H	Ħ	(R)-CH ₂ CH(Me) ₂	Bn	(R) -CO ₂ Me
26 4	Ħ	H	(S)-CH ₂ CH(Me) ₂	Bn	(S) -CO₂Me
265	H	Ħ	(R)-CH ₂ CH(Me) ₂	Bn	(S) -CO₂Me
266	Ħ	Ħ	(S)-CH ₂ CH(Me) ₂	Fmoc	(R) CO ₂ Me
267	Ħ	Ħ	(R)-CH ₂ CH(Me) ₂	Fmoc	(R) CO ₂ Me
268	Ħ	Ħ	(S)-CH ₂ CH(Me) ₂	Fmoc	(S)—CO ₂ Me
269	H	H	(R)-CH ₂ CH(Me) ₂	Fmoc	(S) -CO ₂ Me
270	Ħ	Ħ	(S) Me	H	(R) -CH ₂ OH
271	Ħ	Ħ	(S)-Me	Bn	(R) -CH ₂ OH
· 272	H	Ħ	(S) Me	Fmoc	(R) −CH ₂ OH
273	Ħ	Ħ	(R) Me	H	(R) -CH₂OH
274	H	H	(R)-Me	Bn	(R)—CH ₂ OH
275	Ħ	H	(R) Me	Fmoc	(R) -CH₂OH
276	H	H	(S)-Me	H	(S) -CH ₂ OH

277	H	Ħ	(S) -Me	Bn	(S) -CH ₂ OH
278	H	Ħ	(S) -Me	Fmoc	(S)—CH ₂ OH
279	H	H	(R)-Me	H	(S) -CH ₂ OH
280	H	H	(R)-Me	Bn	(S)—CH₂OH
281	Ħ	Ħ	(<i>R</i>)-Me	Fmoe	(S)—CH ₂ OH
282	Ħ	H	(S)-CH ₂ CH(Me) ₂	H	(R) -CH₂OH
283	H	H	(S)-CH ₂ CH(Me) ₂	Bn	(R) −CH ₂ OH
284	H	H	(S)-CH ₂ CH(Me) ₂	Fmoe	(R) −CH ₂ OH
285	H	H	(R)-CH ₂ CH(Me) ₂	H	(R) −CH ₂ OH
286	Ħ	Ħ	(R)-CH ₂ CH(Me) ₂	Bn	(R)—CH₂OH
287	H	Ħ	(R)-CH ₂ CH(Me) ₂	Fmoc	(R) -CH ₂ OH
288	H	Ħ	(S)-CH ₂ CH(Me) ₂	H	(S)—CH ₂ OH
289	Ħ	H	(S)-CH ₂ CH(Me) ₂	Bn	(S)—CH ₂ OH
290	H	Ħ	(S)-CH ₂ CH(Me) ₂	Fmoc	(S)—CH ₂ OH
291	H	Ħ	(R)-CH ₂ CH(Me) ₂	H	(S) -CH ₂ OH
292	Ħ	H	(R)-CH ₂ CH(Me) ₂	Bn	(S)—CH ₂ OH
293	H	H	(R)-CH ₂ CH(Me) ₂	Fmoc	(S)—CH ₂ OH
294	Ħ	H	(S)-PhCH ₂	H	(R) −CH ₂ OH
295	H	H	(S)-PhCH ₂	Bn	(R) -CH₂OH
296	H	H	(S)—PhCH ₂	Fmoc	(R) -CH₂OH
297	Ħ	H	(R)—PhCH ₂	H	(R) -CH₂OH
298	H	H	(R) PhCH ₂	Bn	(R) -CH₂OH
299	H	Ħ	(R) PhCH ₂	Fmoc	(R) -CH ₂ OH
300	H	Ħ	(S)-PhCH ₂	H ·	(S)—CH₂OH
301	H	Ħ	(S) PhCH ₂	Bn	(S) −CH₂OH
302	Ħ	H	(S)-PhCH ₂	Fmoc	(S)−CH 2 OH
303	Ħ	H	(R) -PhCH ₂	H	(S) -CH₂OH
304	Ħ	H	(R) -PhCH ₂	Bn	(S)—CH₂OH
305	H	H	(R) -PhCH ₂	Fmoc	(S) -CH ₂ OH
L	1		1		

306	H	Ħ	(R)−CH₂OH	Fmoc	(S)—CH ₂ OH
307	H	Ħ	(R)−CH ₂ OH	PhCH ₂	(S) CH₂OH
308	Ħ	Ħ	(R)−CH ₂ OBn	Fmoc	(S) CH₂OH
309	Ħ	Ħ	(R)-CH ₂ OBn	PhCH ₂	(S) -CH₂OH
310	H	Ħ	(R)− CH ₂ OH	Fmoc	(R) -CH₂OH
311	H	Ħ	(R)-CH ₂ OH	PhCH ₂	(R) −CH ₂ OH
312	H	H	(R)-CH ₂ OBn	Fmoc	(R) −CH ₂ OH
313	H	H	(R)−CH ₂ OBn	PhCH ₂	(R) -CH ₂ OH
314	H	H	(S)- CH ₂ OH	Fmoc	(S) CH₂OH
315	H	H	(S)- CH ₂ OH	PhCH ₂	(S)—CH ₂ OH
316	H	Ħ	(S)-CH ₂ OBn	Fmoe	(S) -CH ₂ OH
317	H	H	(S)- CH ₂ OBn	PhCH ₂	(S) -CH ₂ OH
318	H	H	(S)- CH ₂ OH	Fmoc	(<i>R</i>) −CH ₂ OH
319	H	H	(S)- CH₂OH	PhCH ₂	(R) -CH ₂ OH
320	Ħ	H	(S)-CH ₂ OBn	Fmoc	(R) -CH ₂ OH
321	H	Ħ	(S)-CH ₂ OBn	PhCH ₂	(R) -CH₂OH



328	H	Ħ	Boc	Ħ	H	CO₂Me
329	H	H	Boc	H	H	CONHMe
330	H	PhCH ₂	H	H	H	CO₂Me
331	H	PhCH ₂	H	H	H	CONHMe
332	H	PhCH ₂	PhCH ₂	H	Ħ	CO ₂Me
333	Ħ	PhCH ₂	PhCH ₂	Ħ	H	CONHMe
334	H	PhCH ₂	Fmoe	Ħ	H	CO₂Me
335	Ħ	PhCH ₂	Fmoc	Ħ	H	CONHMe
336	Ħ	PhCH ₂	Boc	Ħ	H	CO₂Me
337	H	PhCH ₂	Boe	H	H	CONHMe
338	H	H	H	H	PhCH ₂	CO₂Me
339	H	H	H	H	PhCH ₂	CONHMe
340	H	H	PhCH ₂	H	PhCH ₂	CO ₂ Me
341	H	H	PhCH ₂	H	PhCH ₂	CONHMe
342	H	H	Fmoe	H	PhCH ₂	CO₂Me
343	H	H	Fmoc	H	PhCH ₂	CONHMe
344	H	H	Boe	H	PhCH ₂	CO₂Me
345	Ħ	H	Boc	Ħ	PhCH ₂	CONHMe
346	H	PhCH ₂	H	Ħ	PhCH ₂	CO₂Me
347	H	PhCH ₂	H	H	PhCH ₂	CONHMe
348	Ħ	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	CO₂Me
349	H	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	CONHMe
350	Ħ	PhCH ₂	Fmoc	Ħ	PhCH ₂	CO₂Me
351	H	PhCH ₂	Fmoc	Ħ	PhCH ₂	CONHMe
352	H	PhCH ₂	Boe	H	PhCH ₂	CO₂Me
353	H	PhCH ₂	Boe	Ħ	PhCH ₂	CONHMe
354	Ph	H	H	H	H	CO₂Me
355	Ph	Ħ	H	H	H	CONHMe
356	Ph	Ħ	PhCH ₂	Ħ	H	CO₂Me

357	Ph	Ħ	PhCH ₂	H	H	CONHMe
358	Ph	H	Fmoc	H	H	CO₂Me
359	Ph	H	Fmoc	H	H	CONHMe
360	Ph	H	Boc	H	H	CO₂Me
361	Ph	H	Boc	H	H	CONHMe
362	H	H	H	Ph	H	CO₂Me
363	H	H	H	Ph	H	CONHMe
364	H	H	PhCH ₂	Ph	H	CO ₂Me
365	H	Ħ	PhCH ₂	Ph	H	CONHMe
366	H	·H	Fmoc	Ph	H	CO₂Me
367	H	Ħ	Fmoc	Ph	H	CONHMe
368	H	H	Boc	Ph	H	CO₂Me
369	H	Ħ	Boc	Ph	H	CONHMe
370	Ph	Ħ	H	Ph	Ħ	CO₂Me
371	Ph	Ħ	H	Ph	Ħ	CONHMe
372	Ph	Ħ	PhCH ₂	Ph	Ħ	CO₂Me
373	Ph	Ħ	PhCH ₂	Ph	Ħ	CONHMe
374	Ph	Ħ	Fmoc	Ph	Ħ	CO₂Me
375	Ph	Ħ	Fmoc	Ph	Ħ	CONHMe
376	Ph	Ħ	Boc	Ph	Ħ	CO₂Me
377	Ph	H	Boc	Ph	Ħ	CONHMe
378	Ħ	Ħ	H	H	CH₂OH	CO₂Me
379	Ħ	Ħ	Ħ	Ħ	CH₂OH	CONHMe
380	H	Ħ	PhCH ₂	H	CH₂OH	CO ₂Me
381	H	Ħ	PhCH ₂	H	CH₂OH	CONHMe
382	H	Ħ	Fmoc	H	CH₂OH	CO₂Me
383	H	Ħ	Fmoc	H	CH₂OH	CONHMe
384	H	H	Boe	H	CH₂OH	CO₂Me
385	H	Ħ	Boc	H	CH₂OH	CONHMe

386	Ħ	PhCH ₂	H	H	CH₂OH	CO₂Me
387	Ħ	PhCH ₂	H	Ħ	CH ₂ OH	CONHMe
388	H	PhCH ₂	PhCH ₂	Ħ	CH₂OH	CO₂Me
389	H	PhCH ₂	PhCH ₂	Ħ	CH₂OH	CONHMe
390	H	PhCH ₂	Fmoe	H	CH ₂ OH	CO ₂ Me
391	H	PhCH ₂	Fmoe	Ħ	CH ₂ OH	CONHMe
392	H	PhCH ₂	Boe	H	CH ₂ OH	CO ₂ Me
393	H	PhCH ₂	Boe	H	CH₂OH	CONHMe
394	Ph	H	H	H	CH ₂ OH	CO ₂ Me
395	Ph	H	H	H	CH ₂ OH	CONHMe
396	Ph	H	PhCH ₂	H	CH ₂ OH	CO ₂ Me
397	Ph	Ħ	PhCH ₂	H	CH ₂ OH	CONHMe
398	Ph	Ħ	Fmoc	H	CH ₂ OH	CO ₂ Me
399	Ph	Ħ	Fmoc	Ħ	CH₂OH	CONHMe
400	Ph	Ħ	Boc	Ħ	CH ₂ OH	CO₂Me
401	Ph	Ħ	Boc	Ħ	СЊ∙ОН	CONHMe

Compound	R_1	R_2	R ₃	R' ₁	R' ₂	R ₃	X	Q'
402	Ħ	H	H	H	H	H	θ	CO-NH(CH ₂) ₂ NH-CO
403	Ħ	H	Ħ	H	Ħ	H	Φ	CO-NH(CH ₂) ₄ NH-CO
404	Ħ	Ħ	Ħ	H	H	H	θ	CO-NH(CH ₂) ₆ NH-CO
405	H	H	Ħ	H	Ħ	H	θ	CO-N(C ₂ H ₄)N-CO
406	Ħ	H	PhCH ₂	H	H	PhCH₂	θ	CO-NH(CH₂)₂NH-CO

407	H	H	PhCH ₂	Ħ	Ħ	PhCH ₂	θ	CO-NH(CH ₂) ₄ NH-CO
408	Ħ	H	PhCH ₂	Ħ	Ħ	PhCH ₂	θ	CO-NH(CH ₂) ₆ NH-CO
409	Ħ	H	PhCH ₂	H	H	PhCH ₂	θ	CO-N(C ₂ H ₄)N-CO
410	H	H	PhCH ₂	Ħ	H	PhCH ₂	Ħ	CO-NH(CH ₂) ₂ NH-CO
411	H	H	PhCH ₂	H	H	PhCH ₂	Ħ	CO-NH(CH ₂) ₄ NH-CO
412	Ħ	H	PhCH ₂	Ħ	H	PhCH ₂	Ħ	CO-NH(CH ₂) ₆ NH-CO
413	Ħ	H	PhCH ₂	Ħ	H	PhCH ₂	Ħ	CO-N(C ₂ H ₄)N-CO
414	H	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	0	CO-NH(CH ₂) ₂ NH-CO
415	H	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	θ	CO-NH(CH ₂) ₄ NH-CO
416	Ħ	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	θ	CO-NH(CH ₂) ₆ NH-CO
417	Ħ	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	θ	CO-N(C ₂ H ₄)N-CO
418	H	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	H	CO-NH(CH ₂) ₂ NH-CO
419	H	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	Ħ	CO-NH(CH ₂) ₄ NH-CO
420	H	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	Ħ	CO-NH(CH ₂) ₆ NH-CO
421	H	PhCH ₂	PhCH ₂	Ħ	PhCH ₂	PhCH ₂	Ħ	CO-N(C ₂ H ₄)N-CO
422	Ph	Ħ	PhCH ₂	Ph	Ħ	PhCH ₂	θ	CO-NH(CH ₂) ₂ NH-CO
423	Ph	H	PhCH ₂	Ph	Ħ	PhCH ₂	θ	CO-NH(CH ₂) ₄ NH-CO
424	Ph	· Ħ	PhCH ₂	Ph	H	PhCH ₂	θ	CO-NH(CH ₂) ₆ NH-CO
425	Ph	Ħ	PhCH₂	Ph	H	PhCH ₂	θ	CO-N(C ₂ H ₄)N-CO
426	Ph	H	PhCH₂	Ph	H	PhCH ₂	H	CO-NH(CH ₂) ₂ NH-CO
427	Ph	H	PhCH ₂	Ph	H	PhCH ₂	Ħ	CO-NH(CH ₂) ₄ NH-CO
428	Ph	H	PhCH ₂	Ph	Ħ	PhCH ₂	H	CO-NH(CH ₂) ₆ NH-CO
4 29	Ph	H	PhCH ₂	Ph	H	PhCH ₂	H	CO-N(C₂H₄)N-CO
430	Ph	H	PhCH ₂	Ph	Ħ	PhCH ₂	H	CO-NH(CH ₂) ₂ NH-CO
431	Ph	H	PhCH ₂	Ph	H	PhCH ₂	H	CO-NH(CH ₂) ₄ NH-CO
432	Ph	H	PhCH ₂	Ph	H	PhCH ₂	H	CO-NH(CH ₂) ₆ NH-CO
433	Ph	Ħ	PhCH ₂	Ph	H	PhCH ₂	H	CO-N(C ₂ H ₄)N- CO
434	Ph	H	Ph	Ph	H	Ph	θ	CO-NH(CH ₂) ₂ NH-CO
435	Ph	H	Ph	Ph	H	Ph	θ	CO-NH(CH ₂) ₄ NH-CO

436	Ph	H	Ph	Ph	Ħ	Ph	0	CO-NH(CH ₂) ₆ NH-CO
437	Ph	H	Ph	Ph	并	Ph	θ	CO-N(C ₂ H ₄)N-CO
438	NO ₂ -Ph	H	Ph	NO ₂ -Ph	H	Ph	θ	CO-NH(CH ₂) ₂ NH-CO
439	NO ₂ -Ph	Ħ	Ph	NO₂-Ph	H	Ph	θ	CO-NH(CH ₂) ₃ NH-CO
440	NO ₂ -Ph	H	Ph	NO ₂ -Ph	Ħ	Ph	θ	CO-NH(CH ₂) ₄ NH-CO
441	NO ₂ -Ph	H	Ph	NO ₂ -Ph	H	Ph	0	CO-NH(CH ₂) ₅ NH-CO
442	NO ₂ -Ph	Ħ	Ph	NO₂-Ph	Ħ	Ph	Ð	CO-NH(CH ₂) ₆ NH-CO
443	NO ₂ -Ph	Ħ	Ph	NH ₂ -Ph	H	Ph	θ	CO-N(C ₂ H ₄)N-CO
444	NH ₂ -Ph	H	Ph	NH ₂ -Ph	H	Ph	θ	CO-NH(CH ₂) ₂ NH-CO
445	NH ₂ -Ph	H	Ph	NH ₂ -Ph	Ħ	Ph	θ	CO-NH(CH ₂)₃NH-CO
446	NH ₂ -Ph	H	Ph	NH ₂ -Ph	Ħ	Ph	θ	CO-NH(CH ₂) ₄ NH-CO
447	NH ₂ -Ph	H	Ph	NH ₂ -Ph	Ħ	Ph	θ	CO-NH(CH ₂) ₅ NH-CO
448	NH ₂ -Ph	Ħ	Ph	NH ₂ -Ph	H	Ph	θ	CO-NH(CH ₂) ₆ NH-CO
449	NH ₂ -Ph	H	Ph	NH ₂ -Ph	H	Ph	0	CO-N(C ₂ H ₄)N-CO
450	NO ₂ -Ph	Ħ	Ph	NO ₂ -Ph	H	Ph	Ħ	CO-NH(CH ₂) ₂ NH-CO
451	NO ₂ -Ph	H	Ph	NO ₂ -Ph	H	Ph	H	CO-NH(CH ₂)₃NH-CO
452	NO ₂ -Ph	Ħ	Ph	NO ₂ -Ph	H	Ph	H	CO-NH(CH ₂) ₄ NH-CO
453	NO ₂ -Ph	H	Ph	NO ₂ -Ph	H	Ph	H	CO-NH(CH ₂)₅NH-CO
454	NO ₂ -Ph	Ħ	Ph	NO ₂ -Ph	H	Ph	H	CO-NH(CH ₂) ₆ NH-CO
455	NO ₂ -Ph	H	Ph	NH ₂ -Ph	H	Ph	H	CO-N(C₂H₄)N-CO
456	NH ₂ -Ph	Ħ	Ph	NH ₂ -Ph	Ħ	Ph	H	CO-NH(CH ₂) ₂ NH-CO
457	NH ₂ -Ph	H	Ph	NH ₂ -Ph	H	Ph	H	CO-NH(CH ₂) ₃ NH-CO
458	NH ₂ -Ph	Ħ	Ph	NH ₂ -Ph	H	Ph	H	CO-NH(CH ₂) ₄ NH-CO
459	NH ₂ -Ph	H	Ph	NH ₂ -Ph	Ħ	Ph	H	CO-NH(CH ₂)₅NH-CO
460	NH ₂ -Ph	H	Ph	NH ₂ -Ph	H	Ph	H	CO-NH(CH ₂) ₆ NH-CO
461	NH ₂ -Ph	Ħ	Ph	NH ₂ -Ph	H	Ph	Ħ	CO-N(C₂H₄)N-CO

26. (Previously Presented) The pharmaceutical composition according to claim 22, further comprising pharmaceutically acceptable excipients and/or diluents.

- 27. (Withdrawn) A method of treating:
- i) neurodegenerative, inflammatory, toxic, traumatic, or vascular disorders of the central, peripheral, or autonomic nervous system, neural damages secondary to hypoxia, ischaemia, burns, chemotherapy, toxic compounds of various origin (including alcohol), infections, trauma (including surgical trauma) originating axotomy of motoneurons, sensorial, motor, or sensorimotor neuropathies, or autonomic dysfunctions secondary to diverse pathologies, genetic disorders, nervous pathologies of diverse origin, some ocular pathologies, corneal diseases of diverse origin, pathologies from reduced motility of the gastro-intestinal tract or from urinary bladder atony, endocrine neoplastic pathologies, clinical conditions in which stimulation of learning processes is advantageous, and all pathological conditions originating from apoptotic processes of neural cells;
- ii) acquired immunodeficiency diseases due to reduced or absent bioavailability of NGF;
- iii) conditions in which stimulation of neoangiogenesis may be advantageous;
- iv) certain ocular pathologies,
- said method comprising administering to a patient in need of such a treatment a pharmaceutical composition comprising as active principle at least one among the 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I), or their dimers of general formula (II) and (III), or mixtures thereof as defined in claim 22.
- 28. (Withdrawn) The method according to claim 27, in which said neurodegenerative, inflammatory, toxic, traumatic, or vascular disorders of the central, peripheral, or autonomic nervous system are selected from Alzheimer Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington disease, multiple sclerosis, epilepsy, Down syndrome, nervous deafness and Ménière's disease.
- 29. (Withdrawn) The method according to claim 27, in which said neural damages secondary to infections are selected from polio and HIV virus.

- 30. (Withdrawn) The method according to claim 27, in which said genetic disorders are selected from Charcot-Marie-Tooth disease, Refsum disease, abetalipoprotenemia, Tangier disease, Krabbe disease, metachromatic leukodystrophy, Fabry disease, Dejerine-Sottas disease.
- 31. (Withdrawn) The method according to claim 27, in which said nervous pathologies of diverse origin are selected from diffuse atrophy of cerebral cortex, Lewy body dementia, Pick's disease, mesolimbocortical dementia, neuronal ceroid lipofuscinosis, thalamic degeneration, cortico-striatal-spinal degeneration, cortico-basal ganglionic degeneration, cerebrocerebellar degeneration, familial dementia with spastic paraparesis, polyglucosan bodies disease, Shy-Drager synfrome, olivopontocerebellar atrophy, progressive supranuclear palsy, deforming muscular dystony, Hallervorden-Spatz disease, Meige's syndrome, familial shivering, Gilles de la Tourette syndrome, chorea-acanthocytosis syndrome, Friedreich's ataxia, Holmes' corticocerebellar familial atrophy, Gerstmann-Straussler-Scheinker disease, progressive spinal muscular atrophy, spastic paraplegia, peroneal muscular atrophy, hypertrophic interstitial polyneuropathy and polyneuritic ataxic heredopathy.
- 32. (Withdrawn) The method according to claim 27, in which said ocular pathologies are selected from optic nerve neuropathies, retinal degeneration, ophtalmoplegy and glaucoma; and said corneal diseases of diverse origin are selected from neurotrophic ulcers, post-traumatic and post-infective corneal disorders.
- 33. (Withdrawn) The method according to claim 27, in which said pathologies from reduced motility of the gastro-intestinal tract or from urinary bladder atony are selected from interstitial cystitis and diabetic cystitis.
- 34. (Withdrawn) The method according to claim 27, in which said conditions in which stimulation of neoangiogenesis may be advantageous are selected from myocardial infarction, stroke, cerebral aneurysms, gastro-duodenal ulcers, wound healing and peripheral vasculopathies.

- 35. (Withdrawn) The method according to claim 27, in which said acquired immunodeficiency disease is immunodeficiency of ageing.
- 36. (Withdrawn) A method for promoting growth and/or *in vivo*, *in vitro* or *ex vivo* survival of neuronal cells, comprising using as promoting reagents the 3-aza-bicyclo[3.2.1]octane derivatives of formula (I), their dimers of formula (II) or (III) and mixtures thereof as defined in claim 22.
- 37. (Withdrawn) The method according to claim 36, wherein said neural cells are selected from the group consisting of dopaminergic, cholinergic, sensorial neurons, striatal cells, cortical cells, cells of the corpus striatum, hippocampus, cerebellum, olfactory bulbs, periaqueductal cells, cells of the raphe nuclei, of the locus coeruleus, of the dorsal root ganglia, sympathetic neurons, lower motoneurons, nervous stem cells, and cells anyhow deriving from the neural plaque.
- 38. (Withdrawn) A process for the preparation of culture and storage media useful for conservation of explanted corneas destined to transplantation, comprising adding to culture and storage media 3-aza-bicyclo[3.2.1]octane derivatives of formula (I), their dimers of formula (II) or (III), or mixtures thereof as defined in claim 22.
- 39. (Withdrawn) A method for imaging analysis of tissues and organs containing neurotrophine receptors, comprising using 3-aza-bicyclo[3.2.1]octane derivatives of formula (I), their dimers of formula (II) or (III), or mixtures thereof as defined in claim 22, labelled with suitable reagents (contrast agents, radioisotopes, fluorescent agents etc.), and possibly processed with procedures useful for medical imaging purposes.
- 40. (Withdrawn) The method according to claim 39, for monitoring the use and efficacy of drugs or for the diagnosis of mammal diseases in which the neurothrophine receptors are involved.

41. (Cancelled)

42. (Currently Amended) The 3-aza-bicyclo[3.2.1]octane derivatives of formula (I) and their dimers of formula (II) and (III) according to claim 41, selected from the compounds indicated by the following numbers:

3,4,6,11,14-16,18,22-<u>23</u>,31,33,37,39,41-43,45-57,59,61-63,67-69,71-74,80-82,84-86,88-90,92-94,96-98,100,102,104-137,139-144,146-151,153,155-162,165-167,169-171,173,175,177,179-183,185,187190-191,193196-217321,323,325-461, and as defined in claim 25.